No­var­tis sues FDA over its stance on Sanofi block­buster’s ex­clu­siv­i­ty

No­var­tis’ gener­ic drug sub­sidiary San­doz has sued the FDA, claim­ing the agency is wrong­ly pro­tect­ing Sanofi’s block­buster mul­ti­ple scle­ro­sis drug Auba­gio from gener­ic com­pe­ti­tion. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER